What LongeVC does

LongeVC is a privately-held, Washington D.C.-headquartered venture capital firm founded in 2020 that invests in early-stage biotechnology and longevity-focused companies. The firm deploys capital across three explicit pillars — Therapeutics (pre-clinical and clinical drug development targeting molecular and cellular mechanisms of aging), Diagnostics & Prevention (personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies for faster drug discovery and testing) — and currently operates two funds (Fund I and Fund II) supporting 40+ portfolio companies. Its investment activity is concentrated in named holdings such as Insilico Medicine (AI drug discovery), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), Trogenix (precision oncology, $95M Series A in October 2025), Valink Therapeutics (bsADCs), and Constructive Bio (engineered protein therapeutics), among others.

LongeVC monetizes as a traditional early-stage VC, generating returns through equity stakes in portfolio companies with future liquidity via IPOs, acquisitions, or secondaries; the firm has no disclosed management fees, AUM, or limited partner structure. Beyond capital, the firm offers a curated ecosystem of support: a paid 6-month Venture Fellowship Program (now in its third cohort) that sources graduate-student talent and evaluates potential investments alongside the investment team; an advisory board of scientific luminaries including 2013 Nobel Laureate Michael Levitt, NAS members Vadim Gladyshev and Thomas Rando, longevity researcher Matt Kaeberlein, and AI-bio pioneer Alex Zhavoronkov; and a wholly-owned operating subsidiary, Founders Search Advisors (FSA), launched November 2025 to recruit executive talent for portfolio companies using equity-based compensation. The operating team spans three Managing Partners (Ilya Suharenko, Garri Zmudze, Sergey Jakimov) and additional Partners, Venture Partners, Principals, and a COO and CFO. Distribution and deal sourcing run through direct advisor/fellow networks, the 'Through the Longevity Lens' Substack newsletter, LinkedIn/X channels, industry events, and partnerships with sector bodies such as the Longevity Science Foundation and the Longevity Biotech Association.

Name

LongeVC

Legal name

LongeVC

Website

https://longevc.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

LongeVC is an early-stage venture capital firm headquartered in Washington D.C. that deploys Fund I and Fund II capital across therapeutics, diagnostics, and longevity infrastructure, supporting 40-plus portfolio biotech and longevity companies globally.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Late-Stage Venture Capital (Series C+) (FSANAAAC)

Keywords

• Venture capital
• Biotech investing
• Longevity investing
• Early-stage investment
• Healthcare venture capital

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns / Carry: As a venture capital firm, LongeVC generates returns through equity investments in early-stage biotech companies. Returns come from portfolio company exits via IPOs, acquisitions, or secondary sales. The firm manages Fund I and Fund II, investing across therapeutics, diagnostics and prevention, and longevity infrastructure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

LongeVC is an early-stage venture capital firm that deploys capital into biotech and longevity-focused companies through Fund I and Fund II, with focused investment pillars in Therapeutics, Diagnostics & Prevention, and Longevity Infrastructure. The firm curates an ecosystem of more than 40 portfolio companies and provides strategic guidance, talent acquisition support, and connections to a global network of thought leaders. Complementary offerings include a 6-month paid Venture Fellowship Program and the Founders Search Advisors executive search firm launched in November 2025.

Product overview

LongeVC is a venture capital platform operating as a single, unified investment offering rather than a modular software product. The firm provides venture capital investment services alongside complementary programs including a Venture Fellowship Program for talent development and Founders Search Advisors for executive recruiting. The core investment focus spans three verticals: Therapeutics (pre-clinical and clinical drug development targeting aging mechanisms), Diagnostics & Prevention (early-stage personalized medicine and advanced diagnostics), and Longevity Infrastructure (platform technologies enabling faster drug discovery and testing at scale).

Differentiator

Problem solved

Functional benefit

Brands

• Founders Search Advisors (FSA): Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using equity-based compensation model

Products and services

• LongeVC Investment Platform (Fund I and Fund II) Early-stage venture capital investment platform operated through Fund I and Fund II that invests in exceptional biotech and longevity-focused founders developing therapeutics, diagnostics & prevention, and longevity infrastructure, providing capital alongside ecosystem connections to drive portfolio company advancement.
• Venture Fellowship Program A 6-month, part-time, remote paid fellowship program for graduate students (MS/PhD) and postdoctoral fellows that provides paid exposure to biotech venture investing, including evaluating potential investments, participating in company pitches, and developing strategic initiatives in drug discovery, computational and synthetic biology, and genomic medicine.
• Founders Search Advisors (FSA) Executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model, addressing funding and talent acquisition challenges faced by early-stage longevity biotech companies.

Quantifiable outcome

• Portfolio companies include industry leaders such as Insilico Medicine (AI drug discovery unicorn), Rubedo Life Sciences (senolytics), Turn.bio (mRNA medicines), and The Longevity Science Foundation (non-profit research funding)

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Founders Search Advisors (FSA)coreStrategic or Co-development Partner · 6 November 2025Founders Search Advisors (FSA) is an executive search firm launched by LongeVC to assist longevity biotech startups in recruiting top talent using an equity-based compensation model. The firm addresses funding and talent acquisition challenges faced by early-stage longevity companies.
• The Longevity Science FoundationcoreStrategic or Co-development PartnerThe Longevity Science Foundation is an international non-profit funding early-stage research on extending healthy human lifespan. LongeVC is connected to LSF through shared leadership (Alex Zhavoronkov serves on LSF's Visionary Board) and supports LSF's mission through investment and ecosystem building. LSF has launched campaigns such as the 'Invested in Her' crowdfunding for ovarian aging research.
• Longevity Biotech AssociationcoreStrategic or Co-development PartnerThe Longevity Biotech Association is a portfolio organization and consortium aiming to advance the longevity industry by setting standards, educating stakeholders, and encouraging partnerships.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Andreessen Horowitz (a16z Bio): a16z Bio is the dedicated healthcare and biology investment arm of Andreessen Horowitz, investing in bio companies at the intersection of technology and life sciences. Comparable to LongeVC because of shared interest in AI-driven drug discovery and platform biotech, though a16z Bio operates with far greater resources.
• 8VC: 8VC is a multi-stage venture firm with bio and longevity exposure alongside its broader tech portfolio. Comparable to LongeVC as an early-stage investor in biotech and life-sciences platforms, though 8VC operates across many technology categories beyond longevity.
• Khosla Ventures: Khosla Ventures invests broadly across technology and biotech, including longevity-adjacent therapeutics and diagnostics. Comparable to LongeVC because both deploy early-stage capital into high-impact science, but Khosla operates at much greater AUM scale and across many sectors beyond biotech.
• ARCH Venture Partners: ARCH Venture Partners is one of the largest dedicated biotech and advanced-technology venture firms, with deep exposure to longevity-relevant platforms. Comparable to LongeVC as a science-led biotech investor with Nobel-caliber scientific advisors, but at a substantially larger fund scale.
• Founders Fund: Founders Fund invests across frontier technology sectors including biotech and longevity-adjacent companies. Comparable to LongeVC because both back bold science bets, but Founders Fund is a generalist tech investor with massive fund sizes compared to LongeVC's niche focus.

Regional players

• Longevity Vision Fund: Longevity Vision Fund is a Russia-origin venture fund focused on longevity, biotech, and preventive medicine. Comparable to LongeVC as another dedicated longevity-focused VC, though it serves a different geographic ecosystem and overlaps with LongeVC in shared thesis on aging biology.

Direct peers

• DCVC Bio: DCVC Bio is the dedicated bio and life sciences arm of DCVC, investing in early-stage biotech companies using computational and engineering approaches. Comparable to LongeVC because both target deep-tech biotech at the early stage and share an AI/bio convergence thesis.
• Foresite Capital: Foresite Capital is a dedicated healthcare and biotech venture firm investing across therapeutics, diagnostics, and healthcare infrastructure. Comparable to LongeVC because both deploy capital into science-driven biotech and longevity infrastructure at the early stage.
• Section 32: Section 32 is a venture capital firm that invests in biotech, healthtech, and technology platforms with a science-grounded approach. Directly comparable to LongeVC because both invest early in biotech and aim to back technical founders, though Section 32 is broader in scope beyond longevity.
• Apollo Ventures: Apollo Ventures is a dedicated early-stage venture capital firm focused exclusively on longevity and age-related disease therapeutics. Highly comparable to LongeVC because it competes for the same small pool of longevity-focused biotech founders and shares a similar thesis-driven, science-led investment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hqlongevc
• LinkedInlinkedin.com/company/longevc

Revenue estimate

Valuation estimate

Number of profiles

Profiles28 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments23 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LongeVC